
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure NV demonstrated strong financial growth in 2024, reporting revenues of $27.1 million, representing a significant 71% year-over-year increase, primarily driven by licensing and collaboration revenues despite a decline in contract manufacturing revenue. The company's probability of success for its Huntington's disease gene therapy, AMT-130, has been significantly upgraded to 75%, with expectations for a commercial launch by 2026, bolstered by positive feedback from the FDA. Additionally, the estimated gross pricing for AMT-130 has been increased to $2.5 million, reflecting a strong outlook for the therapy amid positive advancements in regulatory discussions and anticipated approval pathways.
Bears say
The analysis indicates a negative outlook on uniQure NV due to a significant downturn in revenue estimates, now projected to peak at over $2 billion, suggesting diminishing market confidence in its growth trajectory. Additionally, substantial reductions in R&D and SG&A expenses—33% and 29% year-over-year, respectively—reflect serious operational cutbacks, including a drastic workforce reduction and facility sale, which may hinder innovation and long-term sustainability. Despite a cash runway extending into the second half of 2027, concerns about the company's clinical pipeline momentum and the reliability of diagnostic markers raise questions about the overall viability and potential success of its therapeutic developments, particularly in Huntington's disease.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares